OPXA News Alert Opexa Therapeutics (OPXA) 0.80 12/25/2014 06

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Opexa Therapeutics (OPXA) 0.80 $OPXA

Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.20 (unch), MDT: 74.08 (+0.31), PSTI: 2.46 (unch), OSIR: 14.87 (+0.13), OPXA: 0.80 (+0.01), FCSC: 2.38 (+0.04), BAX: 74.45 (-0.04), CYTX: 0.48 (-0.01)

Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg
GlobeNewswire - Tue Dec 16, 2:52PM CST
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature its top five healthcare companies for 2015 on Fox Business nationwide on Tuesday, December 16 at 10:00 p.m. Pacific (1 a.m. ET). The show will also air on Bloomberg Europe on Sunday, December 21 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, December 21 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday, December 21 at 3:30 p.m. HKT.
OPXA: 0.80 (+0.01), ATNM: 6.00 (-0.22), AKER: 3.20 (-0.10), CGIX: 7.12 (+0.06)

Small Cap Profiles: OPXA, NEWC, TRNS, MLER
ACCESSWIRE - Thu Dec 11, 9:35AM CST
WHITEFISH, MT / ACCESSWIRE / December 11, 2014 /
TRNS: 9.80 (-0.10), BIIB: 340.89 (+5.13), OPXA: 0.80 (+0.01), SNY: 46.35 (+0.50)

Opexa Therapeutics Selected as One of the "Top 10 Advanced Therapy Projects to Watch"
Business Wire - Tue Nov 18, 8:02AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced Opexa has been named one of the "Top 10 Advanced Therapy Projects to Watch" by Elsevier Business Intelligence for the second consecutive year. As part of this recognition, Neil K. Warma, Opexa's President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston. Mr. Warma will present on Thursday, November 20 at 2:25 p.m. E.S.T.
OPXA: 0.80 (+0.01)

Pieris Appoints Michael Richman as Supervisory Board Member
Marketwired - Wed Nov 12, 9:15AM CST
Pieris AG announced today the appointment of Michael Richman as a member of its Supervisory Board.
OPXA: 0.80 (+0.01)

Opexa Therapeutics CEO Invited to Join Personalized Medicine Panel at New York CEO Conference
Business Wire - Tue Nov 11, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, Opexa's President and Chief Executive Officer, has been invited as a panel member to participate in the New York CEO Conference. The event will take place November 12 - 13, 2014, at the Apella in New York.
OPXA: 0.80 (+0.01)

Update: Opexa Q3 Earnings, Buyout Thesis Remains Intact
Trevor Lowenthal - at Seeking Alpha - Fri Nov 07, 4:52AM CST

OPXA: 0.80 (+0.01), MRK: 57.46 (+0.25)

Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 3:02PM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today reported financial results for the third quarter ended September 30, 2014 and provided an overview of the Company's recent corporate developments.
OPXA: 0.80 (+0.01)

Opexa reports November 6
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:50AM CST

OPXA: 0.80 (+0.01)

Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 8:00AM CST
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the three months ended September 30, 2014 after the close of trading on Thursday, November 6th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 5:00 P.M. EST on Thursday, November 6th.
OPXA: 0.80 (+0.01)

Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS
Business Wire - Wed Oct 22, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced its partnership with the National Multiple Sclerosis Society, Lone Star Chapter, as a sponsor of the nonprofit's annual Houston area Walk MS fundraisers for the fourth consecutive year.
OPXA: 0.80 (+0.01)

Opexa Therapeutics to Present at Cleveland Clinic's 12th Annual Medical Innovation Summit
Business Wire - Mon Oct 20, 8:03AM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that Neil K. Warma, the Company's President and Chief Executive Officer, has been invited to present at the Cleveland Clinic's 12th Annual Medical Innovation Summit, taking place October 26-29, 2014, in Cleveland, Ohio.
OPXA: 0.80 (+0.01)

Opexa Therapeutics Announces Analyst and Investor Event
Business Wire - Thu Oct 02, 1:09PM CDT
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced that it will hold an Analyst and Investor Event in New York City, New York on Thursday, October 9, 2014.
OPXA: 0.80 (+0.01)

Opexa Strengthens Patent Portfolio with Expansion Into B-cell Diseases and Announces Allowance of 98th T-cell Patent
Business Wire - Mon Sep 29, 8:02AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced the expansion of its intellectual property portfolio. Opexa's intellectual property portfolio has grown to reach 98 issued and validated patents worldwide. Additionally, Opexa is expanding its IP protection to cover B-cell mediated diseases in connection with its recently announced development program in Neuromyelitis Optica.
OPXA: 0.80 (+0.01)

Investors look to Lighten Up on Shares of Opexa Therapeutics, Shares Down 7.6% (OPXA)
Comtex SmarTrend(R) - Thu Sep 25, 11:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's worst performing penny stocks, down 7.6% to $0.85 on 1.3x average daily volume. Thus far today, Opexa Therapeutics has traded 316,000 shares, vs. average volume of 241,000 shares per day. The stock has underperformed the Dow (-7.6% to the Dow's -1.5%) and underperformed the S&P 500 (-7.6% to the S&P's -1.5%) during today's trading.
OPXA: 0.80 (+0.01)

Opexa Therapeutics Up 5.6%, Shares Break Through Resistance (OPXA)
Comtex SmarTrend(R) - Thu Sep 18, 10:37AM CDT
Opexa Therapeutics (NASDAQ:OPXA) is one of today's best performing low-priced stocks, up 5.6% to $1.14 on 1.1x average daily volume. Opexa Therapeutics has traded 211,000 shares thus far today, vs. average volume of 200,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's 0.5%) and outperformed the S&P 500 (5.6% to the S&P's 0.4%) during today's trading.
OPXA: 0.80 (+0.01)

Opexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock
Business Wire - Tue Sep 16, 7:30AM CDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it has terminated the public offering of shares of its common stock previously announced on Monday, September 15, 2014. The termination results from an assessment by Opexa's management that current market conditions are not conducive for an offering on terms that would be in the best interests of Opexa's stockholders. As a result of such termination, no shares will be sold pursuant to the offering.
OPXA: 0.80 (+0.01)

Global and Chinese Stem Cell Industry Report, 2014-2017
M2 - Tue Sep 16, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhmz42/global_and) has announced the addition of the "Global and Chinese Stem Cell Industry Report, 2014-2017" report to their offering. Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients. The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out. Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST's adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD). In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter. Key Topics Covered: 1. Overview of Stem Cell Industry 2. Global Stem Cell Industry Chain 3. China Stem Cell Industry Chain 4. Upstream Enterprises 5. Midstream and Downstream Enterprises Companies Mentioned - Advanced Cell Technology - Athersys - Beike Biotechnology - Celgene - Cryo-Cell International - Cryosite - Cyagen Biosciences - Cytori Therapeutics - Esperite - Golden Meditech - LifeCell International - MEDIPOST - Mesoblast - NeoStem - Opexa Therapeutics - Orthofix International - Osiris Therapeutics - Pluristem Therapeutics - Reneuron - StemCells - Tigenix - Vitro Biopharma - ZhongKe Biopharm - Zhongyuan Union Stem Cell Bioengineering For more information visit http://www.researchandmarkets.com/research/hhmz42/global_and
OPXA: 0.80 (+0.01), PSTI: 2.46 (unch), CYTX: 0.48 (-0.01), OSIR: 14.87 (+0.13), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)

Market Maker Surveillance Report. NPSP, RADA, MGPI, OPXA, RLOC, NETE, Losing Stocks With Lowest Price Friction For Monday, September 15th 2014
M2 - Tue Sep 16, 5:59AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4654 companies with "abnormal" market making, 1512 companies with positive Friction Factors and 3686 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. NPS Pharmaceuticals Inc (NASDAQ:NPSP), Rada Electronic Industries Ltd (NASDAQ:RADA), MGP Ingredients Inc (NASDAQ:MGPI), Opexa Therapeutics Inc (NASDAQ:OPXA), REACHLOCAL INCORPORATION (NASDAQ:RLOC), NET ELEMENT INC (OTC:NETE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
NETE: 1.20 (unch), OPXA: 0.80 (+0.01), RADA: 2.74 (+0.16), NPSP: 35.06 (+1.18), RLOC: 3.52 (-0.18), MGPI: 16.53 (+0.28)

Opexa Therapeutics to issue public offering of common shares
M2 - Tue Sep 16, 5:57AM CDT
Biopharmaceutical company company Opexa Therapeutics (NasdaqCM:OPXA) said on Monday that it plans to offer shares of its common stock in a public offering.
OPXA: 0.80 (+0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 91

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading

Top 5 Most Recently Viewed Articles

Molina Healthcare: A Journey of 20 Years of Returns

Updated Category News Views 197

Molina Healthcare's Impressive Investment Journey Molina Healthcare (NASDAQ: MOH) has consistently outperformed the broader market over the last two decades, achieving an impressive annualized return of 12.15%. As a result, this sector leader has garnered significant attention from investors and analysts alike, showcasing its robust performance in the healthcare industry....

Continue Reading
Nokia's Strategic Buyback Program to Enhance Shareholder Value

Updated Category News Views 232

Nokia's Strategic Share Repurchase Initiative Nokia Corporation (NYSE:NOK) has embarked on a significant share repurchase program aimed at mitigating the dilution effects from recent share issuances. This initiative aligns with the company's ongoing commitment to enhancing shareholder value. Recently, Nokia executed the acquisition of 872,093 shares at an average price of...

Continue Reading
Justin Boots Unveils Stylish New Baby Boot Line for First Steps

Updated Category News Views 185

Introducing Mutton Busters Baby Boots by Justin Boots Justin Boots, a name that captures the essence of Western craftsmanship, has launched an exciting new collection for the tiny trendsetters: Mutton Busters. These infant boots are tailored specifically for babies, ensuring comfort, support, and a stylish touch as they take their first steps into the world. Features...

Continue Reading
Waterdrop Inc. Reports Significant Q3 Growth and Innovation

Updated Category News Views 203

Waterdrop Inc. Reports Impressive Financial Results for Q3 Waterdrop Inc. (NYSE: WDH), a prominent technology platform specializing in insurance and healthcare services, recently announced notable financial outcomes for the quarter that ended on September 30, 2025. This report highlights a commendable net operating revenue of RMB 974.9 million, marking a significant...

Continue Reading
Next Technology Holding Inc. Reports Remarkable H1 2025 Growth

Updated Category News Views 150

Next Technology Holding Inc. Delivers Impressive Financial Results for H1 2025 Next Technology Holding Inc. (NASDAQ: NXTT), a leading technology company focused on AI and Bitcoin investments, has released its financial results, showcasing a remarkable surge in performance for the first half of the year. The company, known for its commitment to creating innovative AI...

Continue Reading